Boston Scientific (NYSE:BSX) Shares Gap Down – Time to Sell?

Boston Scientific Corporation (NYSE:BSX) shares gapped down prior to trading on Wednesday . The stock had previously closed at $46.06, but opened at $42.67. Boston Scientific shares last traded at $45.4940, with a volume of 9,129,601 shares trading hands.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded expectations with adjusted EPS of $0.86 versus the $0.83 consensus and revenue of $5.442 billion versus $5.36 billion. Revenue increased 7.5% year over year, while adjusted EPS rose from $0.75 in the prior-year quarter. Boston Scientific Announces Second-Quarter Results
• Positive Sentiment: Growth was broad-based: Cardiovascular sales increased 8.3%, with particularly strong reported growth in APAC and LACA. U.S. sales rose 6.2%, EMEA 6.1%, APAC 11.2% and LACA 22.4%, while margin expansion also supported the quarterly performance. Boston Scientific Q2 Earnings and Revenue Beat
• Positive Sentiment: The company completed a $2 billion accelerated share repurchase, buying back approximately 40 million shares. It also invested $1.5 billion for a roughly 34% stake in MiRus and an option to acquire its TAVR business, potentially strengthening Boston Scientific’s structural-heart portfolio. Boston Scientific Q2 Revenue Report
• Neutral Sentiment: Boston Scientific received FDA 510(k) clearance for its TruSelect 2.6 Microcatheter, adding a new commercial opportunity, although the immediate financial impact is unclear.
• Negative Sentiment: Management reduced 2026 adjusted EPS guidance to $3.28-$3.32 from $3.34-$3.41 and forecast revenue of $21.2-$21.4 billion, below the approximately $21.6 billion consensus. Third-quarter guidance of $0.80-$0.82 EPS and $5.2-$5.3 billion revenue also trails analyst expectations. Boston Scientific Lowers Annual Profit Forecast
• Negative Sentiment: The outlook reduction reflects slower demand for the Watchman heart device, product-growth moderation and increased competition. A global restructuring plan is expected to involve headcount reductions and $700 million-$800 million of costs through 2029, although management targets approximately $500 million in annual savings. Boston Scientific Cuts Outlook Ahead of Restructuring
• Negative Sentiment: UBS lowered its price target to $74 from $95 while retaining a Buy rating, signaling reduced near-term expectations despite confidence in Boston Scientific’s longer-term prospects. UBS Adjusts Boston Scientific Price Target

Analyst Upgrades and Downgrades

BSX has been the topic of several research reports. Barclays cut their price objective on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research report on Thursday, May 28th. Leerink Partners lowered their price target on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a research note on Thursday, May 28th. Stifel Nicolaus dropped their price objective on Boston Scientific from $75.00 to $65.00 and set a “buy” rating on the stock in a research note on Thursday, June 25th. Royal Bank Of Canada decreased their price objective on shares of Boston Scientific from $100.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Finally, UBS Group reaffirmed a “buy” rating and issued a $74.00 price objective (down from $95.00) on shares of Boston Scientific in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $78.40.

Boston Scientific Trading Up 1.2%

The business has a 50-day moving average price of $46.78 and a two-hundred day moving average price of $63.10. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $69.26 billion, a P/E ratio of 19.50, a P/E/G ratio of 0.87 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.36 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, analysts expect that Boston Scientific Corporation will post 3.35 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has initiated a stock buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its stock is undervalued.

Insiders Place Their Bets

In related news, Director Edward J. Ludwig purchased 3,580 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $56.68 per share, with a total value of $202,914.40. Following the completion of the purchase, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This represents a 16.44% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Cheryl Pegus bought 1,770 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the purchase, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have purchased 9,800 shares of company stock valued at $554,012. 0.34% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Boston Scientific

Institutional investors have recently bought and sold shares of the stock. FWL Investment Management LLC purchased a new stake in Boston Scientific during the second quarter worth about $26,000. Swiss RE Ltd. purchased a new position in shares of Boston Scientific in the fourth quarter worth about $26,000. Garton & Associates Financial Advisors LLC bought a new position in Boston Scientific in the 4th quarter worth approximately $26,000. Bangor Savings Bank raised its holdings in Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 142 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd bought a new position in shares of Boston Scientific in the first quarter worth $28,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.